Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 11, 2025
Humacyte (Nasdaq: HUMA), a clinical-stage biotechnology company focused on developing bioengineered human tissue, has scheduled its Q2 2025 financial results and corporate update for August 11, 2025, at 8:00 AM ET.
The company will host a conference call and webcast, accessible to U.S. investors at 1-877-704-4453 and international investors at 1-201-389-0920 using Conference ID 13754596. The webcast will be available 15 minutes before the call and remain accessible for at least 30 days afterward on the company's investor relations website.
Humacyte (Nasdaq: HUMA), un'azienda biotecnologica in fase clinica specializzata nello sviluppo di tessuti umani bioingegnerizzati, ha programmato la pubblicazione dei suoi risultati finanziari del secondo trimestre 2025 e un aggiornamento aziendale per il 11 agosto 2025, alle 8:00 ET.
L'azienda terrà una conference call e una webcast, accessibili agli investitori statunitensi al numero 1-877-704-4453 e agli investitori internazionali al 1-201-389-0920 utilizzando l'ID conferenza 13754596. La webcast sarà disponibile 15 minuti prima della chiamata e resterà accessibile per almeno 30 giorni successivi sul sito web delle relazioni con gli investitori dell'azienda.
Humacyte (Nasdaq: HUMA), una empresa biotecnológica en etapa clínica enfocada en el desarrollo de tejidos humanos bioingenierizados, ha programado sus resultados financieros del segundo trimestre de 2025 y actualización corporativa para el 11 de agosto de 2025 a las 8:00 AM ET.
La compañía realizará una llamada en conferencia y una transmisión web, accesibles para inversores en EE.UU. al 1-877-704-4453 y para inversores internacionales al 1-201-389-0920 usando el ID de conferencia 13754596. La transmisión estará disponible 15 minutos antes de la llamada y permanecerá accesible por al menos 30 días después en el sitio web de relaciones con inversionistas de la compañía.
Humacyte (나스닥: HUMA)는 생체공학 인간 조직 개발에 중점을 둔 임상 단계의 바이오테크 기업으로, 2025년 2분기 재무 결과 및 기업 업데이트를 2025년 8월 11일 오전 8시 ET에 발표할 예정입니다.
회사는 미국 투자자는 1-877-704-4453, 국제 투자자는 1-201-389-0920으로 접속 가능한 컨퍼런스 ID 13754596를 사용하여 컨퍼런스 콜과 웹캐스트를 진행합니다. 웹캐스트는 통화 15분 전에 시작되며 회사의 투자자 관계 웹사이트에서 최소 30일간 시청할 수 있습니다.
Humacyte (Nasdaq : HUMA), une société biotechnologique en phase clinique spécialisée dans le développement de tissus humains bio-ingénierés, a programmé la publication de ses résultats financiers du deuxième trimestre 2025 et une mise à jour d'entreprise pour le 11 août 2025 à 8h00 ET.
La société organisera une conférence téléphonique et une webdiffusion, accessibles aux investisseurs américains au 1-877-704-4453 et aux investisseurs internationaux au 1-201-389-0920 en utilisant l'ID de conférence 13754596. La webdiffusion sera disponible 15 minutes avant l'appel et restera accessible pendant au moins 30 jours après sur le site des relations investisseurs de la société.
Humacyte (Nasdaq: HUMA), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung bioengineerter menschlicher Gewebe spezialisiert hat, hat die Veröffentlichung seiner Finanzergebnisse für das zweite Quartal 2025 und ein Unternehmensupdate für den 11. August 2025 um 8:00 Uhr ET geplant.
Das Unternehmen wird eine Telefonkonferenz und ein Webcast veranstalten, die für US-Investoren unter 1-877-704-4453 und für internationale Investoren unter 1-201-389-0920 mit der Konferenz-ID 13754596 zugänglich sind. Der Webcast wird 15 Minuten vor Beginn der Telefonkonferenz verfügbar sein und mindestens 30 Tage danach auf der Investor-Relations-Website des Unternehmens abrufbar bleiben.
- None.
- None.
DURHAM, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the quarter ended June 30, 2025, on Monday, August 11, 2025. Management will host a webcast and conference call at 8:00 a.m. ET to provide a corporate and financial update.
| Title: | Humacyte Second Quarter 2025 Financial Results and Corporate Update |
| Date: | August 11, 2025 |
| Time: | 8:00 AM Eastern Time |
| Conference Call Details: | 1-877-704-4453 (U.S. Investors Dial) 1-201-389-0920 (International Investors Dial) 13754596 (Conference ID) |
| Call meTM Feature: | Click Here |
| Webcast: | Click Here |
The webcast should be accessible 15 minutes prior to the conference call’s start time. A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the investors section of the Company’s website for at least 30 days.
About Humacyte
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Biologics License Application for the acellular tissue engineered vessel (ATEV) in the vascular trauma indication was approved by the FDA in December 2024. ATEVs are also currently in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte’s 6mm ATEV for urgent arterial repair following extremity vascular trauma and for advanced PAD also have received an RMAT designations. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.
For uses other than the FDA approval in the extremity vascular trauma indication, the ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.
Humacyte Investor Contact:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com
investors@humacyte.com
Humacyte Media Contact:
Rich Luchette
Precision Strategies
+1-202-845-3924
rich@precisionstrategies.com
media@humacyte.com
FAQ
When will Humacyte (HUMA) report Q2 2025 earnings?
How can investors access Humacyte's Q2 2025 earnings call?
What does Humacyte (HUMA) do as a company?
How long will Humacyte's Q2 2025 earnings webcast be available?
